SciSparc’s Bold Move: Acquiring Endoscopy Patents to Turbo‑Boost CNS Therapy
How SciSparc’s patent‑treasury buy‑out could pivot its Nasdaq stock from niche cannabinoid research to high‑impact CNS endoscopy tech—and what that means for investors.
3 minutes to read

